Table 2 Antibiotic distribution in the entire cohort and in patients with community-acquired and nosocomial sepsis
Antibiotics | Global n= 1,372 | Community-acquired n= 1,022 (74.5%) | Nosocomial n= 350 (25.5%) | P |
|---|---|---|---|---|
β-lactams | 902 (65.7%) | 708 (69.3%) | 194 (55.4%) | <0.001 |
Carbapenems | 345 (25.1%) | 218 (21.3%) | 127 (36.3%) | <0.001 |
Quinolones | 282 (20.6%) | 241 (23.6%) | 41 (11.7%) | <0.001 |
Aminoglycosides | 183 (13.3%) | 114 (11.2%) | 69 (19.7%) | <0.001 |
Macrolides | 60 (4.4%) | 54 (5.3%) | 6 (1.7%) | 0.004 |
Anti-gram-positive | 161 (11.7%) | 96 (9.4%) | 65 (18.6%) | <0.001 |
Antifungals | 38 (2.8%) | 20 (2.0%) | 18 (5.1%) | 0.004 |
Others | 151 (11.0%) | 111 (10.9%) | 40 (11.4%) | 0.767 |